GetTopicDetailResponse(id=e0a48e418e, topicName=HER2陽(yáng)性轉(zhuǎn)移性胃癌, introduction=HER2陽(yáng)性轉(zhuǎn)移性胃癌, content=null, image=null, comments=3, allHits=1142, url=https://h5.medsci.cn/topic?id=8741, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=99064, tagList=[TagDto(tagId=99064, tagName=HER2陽(yáng)性轉(zhuǎn)移性胃癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1768920, encodeId=9e7f1e68920be, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2陽(yáng)性轉(zhuǎn)移性胃癌#</a>, objectTitle=抗體藥物偶聯(lián)物Enhertu達(dá)到HER2陽(yáng)性轉(zhuǎn)移性胃癌注冊(cè)研究的主要終點(diǎn), objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=76, createdTime=2020-03-05, rootId=0, userName=ms3046638856685384, userId=659e37938470, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗體藥物偶聯(lián)物Enhertu達(dá)到HER2陽(yáng)性轉(zhuǎn)移性胃癌注冊(cè)研究的主要終點(diǎn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1768921, encodeId=80481e6892108, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2陽(yáng)性轉(zhuǎn)移性胃癌#</a>, objectTitle=FDA授予靶向HER2的抗體藥物偶聯(lián)物ENHERTU突破性療法稱號(hào)，以治療HER2陽(yáng)性轉(zhuǎn)移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=135, createdTime=2020-06-14, rootId=0, userName=ms3046638856685384, userId=659e37938470, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗體藥物偶聯(lián)物ENHERTU突破性療法稱號(hào)，以治療HER2陽(yáng)性轉(zhuǎn)移性胃癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2陽(yáng)性轉(zhuǎn)移性胃癌#</a>, objectTitle=GUT：HER2陽(yáng)性轉(zhuǎn)移性胃癌患者曲妥珠單抗耐藥機(jī)制研究進(jìn)展, objectType=article, longId=150583, objectId=c84815058345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84815058345, replyNumber=0, likeNumber=76, createdTime=2019-01-30, rootId=0, userName=ms3046638856685384, userId=659e37938470, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84815058345, moduleTitle=GUT：HER2陽(yáng)性轉(zhuǎn)移性胃癌患者曲妥珠單抗耐藥機(jī)制研究進(jìn)展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c84815058345)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
